Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Thirty-Two Products Developed for Immunophenotyping of Hematologic Malignancies

By LabMedica International staff writers
Posted on 14 Apr 2011
Thirty-two new clinical flow cytometry reagents have been developed for immunophenotyping of hematologic malignancies.

A provider of reagents for multicolor flow cytometry has expanded its portfolio of antibodies, fluorochromes, and reagents for diagnostics, immunology, oncology, cell biology, and stem cell biology.

eBioscience (San Diego, CA, USA) manufactures the clinical reagents under The Good Manufacturing Practice (GMP) environment. More...
The company assures good signal to noise and more than 90% purity.

The Clinical Flow Cytometry Reagent product line was developed and optimized by eBioscience for the clinical laboratory user. The antibodies are packaged in flexible sizes to help manage precise budgets. All sizes are formulated at 5 µL/test to ensure efficient multicolor immunophenotyping by reducing the ratio of reagent solution to sample volume--critical for conserving precious samples. The wide selection of fluorochrome formats are needed for the variety of cytometers now found in clinical laboratories.

The American Association for Cancer Research (AACR) 102nd Annual Meeting, (April 2–6, 2011) in Orlando (FL, USA) and the XXVI Congress of the International Society for Advancement of Cytometry (CYTO2011), May 2011 in Baltimore, (MD, USA) are showcasing eBioscience's expanding portfolio of clinical reagents.

Related Links:
eBioscience


New
Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.